Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder
Brief Summary: The investigators' hypothesis is that add-on varenicline will be effective (versus placebo) in initiating abstinence from smoking in subjects with stable, euthymic bipolar disorder who are motivated to quit smoking within four weeks. This primary outcome will be assessed from randomization to 12 weeks or end of the treatment phase of the study. Secondarily, the investigators also hypothesize that varenicline will prevent relapse in the subsequent 12-weeks follow-up non-treatment phase. Furthermore, the investigators plan to test the effectiveness of varenicline in reducing nicotine withdrawal symptoms or urges to smoke, as well as its safety for use in stable bipolar patients when used as an add-on treatment for smoking cessation.

The investigators plan to test these hypotheses by conducting a randomized, placebo-controlled add-on treatment trial of Chantix with 60 recruited subjects diagnosed with DSM-IV bipolar disorder for a period of three months. The investigators will follow-up with them three months later to evaluate extended abstinence.


Options:
A: Arm Label: CPT+ICSC; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy (CPT), Drug: Bupropion, Drug: nicotine replacement therapy (NRT), Behavioral: Integrated Care for Smoking Cessation (ICSC), Behavioral: smokefreeVET | Arm Label: ICSC only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy (NRT), Behavioral: Integrated Care for Smoking Cessation (ICSC), Behavioral: smokefreeVET | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy (CPT); Assigned to Arm(s): CPT+ICSC | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): CPT+ICSC, ICSC only | Intervention Type: DRUG; Name: nicotine replacement therapy (NRT); Assigned to Arm(s): CPT+ICSC, ICSC only | Intervention Type: BEHAVIORAL; Name: Integrated Care for Smoking Cessation (ICSC); Assigned to Arm(s): CPT+ICSC, ICSC only | Intervention Type: BEHAVIORAL; Name: smokefreeVET; Assigned to Arm(s): CPT+ICSC, ICSC only
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch

Answer: B